Biora Therapeutics announced completion of the single-ascending dose cohorts for its phase 1, first-in-human clinical study of BT-600 in healthy adult volunteers. BT-600 is a drug-device combination consisting of the orally administered NaviCap device which delivers a unique, liquid formulation of tofacitinib to the colon for the potential treatment of moderate to severe ulcerative colitis.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BIOR:
- Biora Therapeutics Announces Participation in Canaccord Genuity Inflammatory Bowel Disease Symposium
- Biora Therapeutics Announces Participation in Fireside Chat Hosted by H.C. Wainwright & Co.
- Biora Therapeutics announces 2023 anticipated milestones
- Biora Therapeutics initiates Phase 1 clinical study of BT-600
- Biora Therapeutics Announces Initiation of Phase 1 Clinical Study of BT-600
